A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma
Latest Information Update: 17 Nov 2026
At a glance
- Drugs Safusidenib (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms G203; SIGMA
- Sponsors AnHeart Therapeutics; Nuvation Bio
Most Recent Events
- 11 Nov 2026 According to a Nuvation Bio media release, trial overview will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting taking place November 12 to 15, 2026, in Philadelphia, PA.
- 29 Oct 2026 According to a Nuvation Bio media release, phase 3 SIGMA study evaluating safusidenib will expand its study sites to the United Kingdom, France, Sweden, Germany, Italy and Spain, in addition to the United States, Australia, China, Canada and Japan, where the study is currently enrolling or expected to begin enrolment
- 20 Aug 2026 According to Nuvation Bio media release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib. If relevant criteria are met, the designation may allow for rolling review of a marketing application, permitting completed sections to be submitted for FDA review as they become available, rather than waiting for the entire application to be complete.